Nuclear factor-κB (NF-κB) is a family of highly regulated dimeric transcription factors that play pivotal roles in inflammatory responses and immunological reactions. Although they are often activated concurrently, classical and alternative NF-κB activation pathways have distinct regulatory functions, producing secondary inflammatory responses and regulating lymphoid organ development, respectively. As NF-κB functions in the proliferation, differentiation, and survival of lymphocytes, increased activation also participates in the oncogenesis of many lymphoid malignancies. Aberrant NF-κB activation in these tumor cells results from genetic changes or the activation of NF-κB pathways by indirect mechanisms. Recent observations have suggested that NF-κB provides many of the requirements for cellular transformation. Bcl-3, a member of the IκB family, is overexpressed in t (2 ; 5)+ anaplastic large cell lymphoma due to genetic and epigenetic alterations. The different contributions of the classical and alternative NF-κB pathways to tumorigenesis, however, are not well understood. The clinical importance of NF-κB is also being recognized, with the approval of the NF-κB inhibitor bortezomib for treatment of advanced multiple myeloma. A better understanding of the molecular pathways involving NF-κB will surely contribute to more sophisticatedly targeted treatments for malignancies in the future.
No takes yet. Share an insight, caveat, or question.
Momoko Nishikori (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: